Little Bytes News: Castle Biosciences' DecisionDx(r)-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

Patty Garza